Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma.
Kovacsovics-Bankowski M, Sweere JM, Healy CP, Sigal N, Cheng LC, Chronister WD, Evans SA, Marsiglio J, Gibson B, Swami U, Erickson-Wayman A, McPherson JP, Derose YS, Eliason AL, Medina CO, Srinivasan R, Spitzer MH, Nguyen N, Hyngstrom J, Hu-Lieskovan S. Kovacsovics-Bankowski M, et al. Among authors: erickson wayman a. J Immunother Cancer. 2024 Jan 17;12(1):e008056. doi: 10.1136/jitc-2023-008056. J Immunother Cancer. 2024. PMID: 38233101 Free PMC article.
A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J, McPherson JP, Kovacsovics-Bankowski M, Jeter J, Vaklavas C, Swami U, Grossmann D, Erickson-Wayman A, Soares HP, Kerrigan K, Gibson B, Doherty JA, Hyngstrom J, Hardikar S, Hu-Lieskovan S. Marsiglio J, et al. Among authors: erickson wayman a. Front Immunol. 2023 Aug 21;14:1229823. doi: 10.3389/fimmu.2023.1229823. eCollection 2023. Front Immunol. 2023. PMID: 37671166 Free PMC article.
Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis.
Williamson J, Fadlullah MZH, Kovacsovics-Bankowski M, Gibson B, Swami U, Erickson-Wayman A, Jamison D, Sageser D, Jeter J, Bowles T, Cannon DM, Haaland B, Schroeder JD, Nix D, Atkinson A, Hyngstrom J, McPherson J, Tan AC, Hu-Lieskovan S. Williamson J, et al. Among authors: erickson wayman a. Res Sq [Preprint]. 2023 Jun 1:rs.3.rs-2997157. doi: 10.21203/rs.3.rs-2997157/v1. Res Sq. 2023. PMID: 37398360 Free PMC article. Preprint.